Roche announced that it has entered into agreement to acquire Vienna-based, private biotech firm Dutalys and its proprietary DutaMab technology for the discovery and development of fully human, bi-specific antibodies.
Israeli clinical-stage biopharmaceutical company BioLineRX announced that it has signed up Swiss pharma giant Novartis in a multi-year strategic collaboration to develop and commercialize Israeli-sourced drug candidates.
Merck announced that it has acquired Swiss-based oncology firm OncoEthix through a subsidiary. The acquisition gives Merck access to an investigational drug in development for the treatment of blood malignancies and late-stage solid tumors.
Novartis company, Alcon Laboratories, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Xtoro (finafloxacin otic suspension) as treatment for acute otitis externa, also known as “swimmer’s ear.”
CMC Biologics announced that it has entered into agreement with OncoSynergy for accelerated process development and Good Manufacturing Practices (GMP) production for the investigational drug OS2966 targeting the Ebola virus.
AstraZeneca presented new data for its investigational drug Faslodex (fulvestrant) as treatment for hormone-receptor positive breast cancer compared to Arimidex (anastrozole) at the recent 2014 San Antonio Breast Cancer Symposium (SABCS).
Pfizer announced it has partnered with Miami-based OPKO Health to develop the latter's long-acting hGH-CTP as treatment for growth hormone deficiency (GHD) syndrome in both adults and children, as well as for growth failure in children born small for gestational age (SGA) who fall short of catch-up growth standard by 2 years old.